Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore credit cards that provide flexible redemption options. Redeem your rewards in the way that suits you best.
24,184 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Lawmakers delay a major stablecoin bill, triggering renewed frustration across crypto traders as markets react to pol...
Palantir delivered an 85% year-over-year revenue surge in Q1 2026 and lifted full-year targets, but the shares are do...
A rare macro diamond pattern on XRP draws attention as traders weigh a potential long-range breakout. Analysts stress...
Oil markets are in flux, and Occidental faces a pivotal year. This guide breaks down what to expect from occidental (...
Investors are watching Friday’s April payroll report for signs that businesses really starting hire signals a broader...
XRP sits in a tight range around $1.40 as analysts map the path to a potential break all-time high this year. The out...
With quantum threats rising, bitcoin developers might permanently consider a staged freeze of Satoshi’s legendary sta...
As 2026 unfolds, smart glasses are poised for a pivotal year, led by Meta and Google. Apple sits on the sidelines wit...
XRP flashed a fresh TD Sequential buy signal on the 4-hour chart, renewing bets on a sharp advance as traders eye key...
Tariffs launched during the Trump era reshaped some prices and supply chains, but their overall effect on the trade b...
May often stirs market chatter about seasonal weakness, yet patient investors can find lasting value. Here are two gr...